Literature DB >> 18579388

Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action.

Qing Ling1, Yue Huang, Yueyang Zhou, Zhengliang Cai, Bing Xiong, Yahui Zhang, Lanping Ma, Xin Wang, Xin Li, Jia Li, Jingkang Shen.   

Abstract

A novel synthesis of the human leukocyte common antigen-related (LAR) phosphatase inhibitor, illudalic acid, has been achieved by a route more amenable to structure modifications. A series of simpler analogues of illudalic acid was synthesized and evaluated for potency in inhibiting LAR. The structure-activity relationship (SAR) study has shown that the 5-formyl group and the hemi-acetal lactone are crucial for effective inhibition of LAR activity, and are the key pharmacophores of illudalic acid. The fused dimethylcyclopentene ring moiety evidently helps to enhance the potency of illudalic acid against LAR. A preliminary study of the mechanism of action of illudalic acid against LAR was conducted using electrospray ionization mass spectrometry (ESI-MS) and molecular docking techniques. The results are in full agreement with the described mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579388     DOI: 10.1016/j.bmc.2008.06.014

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Identification of novel, less toxic PTP-LAR inhibitors using in silico strategies: pharmacophore modeling, SADMET-based virtual screening and docking.

Authors:  Dara Ajay; M Elizabeth Sobhia
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

2.  Synthesis of "neoprofen", a rigidified analogue of ibuprofen, exemplifying synthetic methodology for altering the 3-D topology of pharmaceutical substances.

Authors:  Ron R Ramsubhag; Chelsea L Massaro; Christina M Dadich; Andrew J Janeczek; Tung T Hoang; Elizabeth A Mazzio; Suresh Eyunni; Karam F A Soliman; Gregory B Dudley
Journal:  Org Biomol Chem       Date:  2016-08-16       Impact factor: 3.876

3.  Synthesis of illudalic acid and analogous phosphatase inhibitors.

Authors:  Harvey F Fulo; Nicole J Rueb; Robert Gaston; Paratchata Batsomboon; Kh Tanvir Ahmed; Amy M Barrios; Gregory B Dudley
Journal:  Org Biomol Chem       Date:  2021-12-15       Impact factor: 3.876

4.  Small Molecules Targeting PTPσ-Trk Interactions Promote Sympathetic Nerve Regeneration.

Authors:  Matthew R Blake; Ryan T Gardner; Haihong Jin; Melanie A Staffenson; Nicole J Rueb; Amy M Barrios; Gregory B Dudley; Michael S Cohen; Beth A Habecker
Journal:  ACS Chem Neurosci       Date:  2022-02-14       Impact factor: 5.780

5.  Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.

Authors:  Ian M Henderson; Fanxun Zeng; Nazmul H Bhuiyan; Dan Luo; Maria Martinez; Jane Smoake; Fangchao Bi; Chamani Perera; David Johnson; Thomas E Prisinzano; Wei Wang; George R Uhl
Journal:  Biochem Pharmacol       Date:  2021-12-02       Impact factor: 6.100

Review 6.  PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Authors:  George R Uhl; Maria J Martinez
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

7.  Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.

Authors:  George R Uhl; Maria J Martinez; Paul Paik; Agnieszka Sulima; Guo-Hua Bi; Malliga R Iyer; Eliot Gardner; Kenner C Rice; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.